I just had a call too. Said no interest in current offer and...

First 4 Last

Share
Profile

Follow
Ranger75

90 Posts.

3

11/07/22

15:22

Post #: 62477727
Share

Originally posted by maria1240: ↑

Just got the second call from Computershare on behalf of the board. He said that he contacted me because I am the top 100 holders and also last time, my feedback was very informative. I told him we have 4 accounts and 3mil shares, I know we are definitely within top 50. He asked me what I think of 14.5c given we just recently received Japanese patent approval. I told him that is not the only catalyst rap has received. He started laughing saying ok, what do you think is the fair price for the acquisition. I said, the fact metagate is willing to extend the agreement tells me the upcoming quarterly can't be bad. If no one is using rap, metagate won't bother extend the agreement. So we now have 4 catalysts: japanese patent, FDA for sleepcheck, metagate extension and upcoming quarterly. If each is worth extra 5c, I believe the fair price should be 35c. For that, I have been conservative. I said I don't know what game Pfizer is playing, but it'd be better for it to increase the price and close the deal asap for Pfizer's sake. Because if resmed or Philip is going to strike a deal with us for using sleepcheck, it will be higher than this. I also said if Pfizer walks away, I think rap can do a Cr at 10c and I will be more than happy to participate. Finally I said to the guy that the board could just save money and don't send the scheme as it will be a waste of money at this price. In the end he did say he will pass on the information to bod. But I am not sure whether it will make any difference for the Bod or for me. It will be a big no at this price.

Expand

I just had a call too. Said no interest in current offer and would need to be more than 30c to get me looking at it.

RAP Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
27 Upvote

0 Great analysis

Reply

Top Stories

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

OPL

Opyl forms JV with UK and US consortium to bring products to the world

HXL

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

AAI

NYSE-listed Alcoa Corp joins ASX through key JV acquisition